Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
Mitotane is widely used for the treatment of adrenocortical cancer (ACC), although the drug-related toxicity complicates its use. The aim of this study is to assess comprehensively the different endocrine and metabolic unwanted effects of the drug, and to provide data on the supportive therapies. We...
Main Authors: | Vittoria Basile, Soraya Puglisi, Anna Calabrese, Anna Pia, Paola Perotti, Alfredo Berruti, Giuseppe Reimondo, Massimo Terzolo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/9/2615 |
Similar Items
-
Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
by: Soraya Puglisi, et al.
Published: (2019-11-01) -
Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
by: Jonathan Poirier, et al.
Published: (2020-03-01) -
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
by: Vittoria Basile, et al.
Published: (2021-04-01) -
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
by: Antonina Germano, et al.
Published: (2020-04-01) -
Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
by: Soraya Puglisi, et al.
Published: (2020-03-01)